Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
The lichen planus market is showing promising growth, driven by advances in treatment options and increasing awareness of autoimmune skin conditions. As more patients receive diagnoses and therapies improve, this sector is expected to expand steadily in the coming years. Let’s explore the current market size, key growth factors, segmentation, innovation trends, leading companies, and regional insights shaping this field.
Lichen Planus Market Size and Forecasted Expansion
The market for lichen planus has experienced substantial growth recently, and projections indicate it will increase from $1.26 billion in 2025 to $1.35 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.1%. This upward trend can be linked to better diagnosis of autoimmune skin disorders, wider availability of corticosteroid treatments, growth in specialized dermatology clinics, heightened clinical awareness, and the use of phototherapy. Looking ahead, the market is expected to reach $1.76 billion by 2030, growing at a CAGR of 6.8%. The forecasted growth is supported by a rising demand for advanced immunotherapies, greater emphasis on managing symptoms over the long term, expansion of biologic drug research, integration of digital dermatology tools, and innovations in targeted anti-inflammatory medications. Key trends shaping this period include increased use of targeted immunomodulatory therapies, combination treatments involving topical and systemic approaches, a focus on chronic disease management, personalized dermatology care, and enhanced patient education and monitoring.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24279&type=smp
Growing Prevalence of Autoimmune Diseases as a Market Driver
One of the main factors boosting the lichen planus market is the rising occurrence of autoimmune diseases. These disorders occur when the immune system mistakenly attacks the body’s healthy cells, encompassing conditions such as rheumatoid arthritis, lupus, type 1 diabetes, multiple sclerosis, and psoriasis. Genetic factors play a significant role in this increase, with certain gene variations affecting immune regulation and connective tissue health. This overall rise in autoimmune diseases contributes directly to more cases of lichen planus. For example, data from June 2024 by the Australian Institute of Health and Welfare indicated that about 514,000 people (2.0% of the population) were living with rheumatoid arthritis in 2022. This condition accounted for 2.0% of total disease burden and 16% of musculoskeletal disorders in 2023, with 1,322 deaths (5.1 per 100,000 population) reported in 2022, representing 0.7% of all deaths. Such statistics highlight how increasing autoimmune disease prevalence fuels demand within the lichen planus market.
Segment Overview of the Lichen Planus Market
This market is divided into several important segments to better understand growth opportunities. By disease type, it covers Lichen Planus, Oral Lichen Planus, Genital Lichen Planus, and Lichen Planus Pigmentosus. Treatment types include topical therapies, systemic therapies, and phototherapy. Routes of administration are classified as topical, oral, and intravenous. End users comprise hospitals, homecare settings, specialty clinics, and other consumers. Each of these categories further breaks down into subtypes; for instance, Lichen Planus includes papular, hypertrophic, actinic, linear, and annular forms; Oral Lichen Planus involves reticular, erosive, atrophic, plaque-like, and bullous variants; Genital Lichen Planus features erosive, papular, annular types, plus vulvovaginal-gingival syndrome; and Lichen Planus Pigmentosus is segmented into diffuse, blotchy, linear, perifollicular, and flexural types. This detailed segmentation helps identify specific areas of growth within the broader market.
Access The Complete Lichen Planus Market Report:
https://www.thebusinessresearchcompany.com/report/lichen-planus-global-market-report
Innovations and New Developments Shaping the Lichen Planus Market
Leading players in this market are focusing on innovative drug delivery systems, such as liposomal formulations, which improve targeted therapy and minimize systemic side effects. Liposomes are tiny spherical vesicles made from lipid bilayers that encapsulate active drug ingredients, enhancing stability and absorption while allowing precise delivery to affected areas. For example, in February 2025, Lipella Pharmaceuticals Inc., a US biotechnology firm, received FDA approval for an expanded access program (EAP) for LP-310, a liposomal tacrolimus formulation designed to treat oral lichen planus. This program enables patients with serious or life-threatening conditions and unmet treatment needs to access the drug outside of clinical trials before full approval, suggesting potential benefits for improved patient outcomes.
Top Companies Leading the Lichen Planus Market
The lichen planus market features several prominent pharmaceutical and biotechnology companies, including Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd, Amneal Pharmaceuticals Inc., Hikma Pharmaceuticals plc, LEO Pharma A/S, Basilea Pharmaceutica Ltd., UCB S.A., Almirall SA, and Lipella Pharmaceuticals Inc. These organizations play key roles in developing treatments and driving innovation within the lichen planus space.
Regional Insights Highlighting North America’s Market Leadership
In 2025, North America held the largest share of the lichen planus market globally. The report also covers major regions such as Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, providing a comprehensive view of global market trends and growth potential. While North America currently leads in revenue generation, emerging markets are expected to contribute significantly in the coming years.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model